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ANUMBER ofclinical andstatistical observationsledto the suggestion (Boyland,
Wallace and Williams, 1955) that patients suffering from cancer of the bladder
excrete carcinogenic substances in the urine. The investigation of Bonser, Brad-
shaw, Clayson and Jull (1956) and ofAllen, Boyland, Dukes, Horning andWatson
(1957) indicate that a number ofortho-aminophenols can induce cancer in experi-
menta lanimals. Two ortho-aminophenols, both metabolites of tryptophan, are
normally present in urine and these substances, 3-hydroxyanthranilic acid and
3-hydroxykynurenine, have produced tumours when implanted in the bladders of
mice (Allen et al, 1957). Both 3-hydroxyanthranilic acid and 3-hydroxykynure-
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FIG. 1.-The equilibrium between naturally occurring ortho-aminophenols
and the corresponding detoxication products.
nine were shown to be present in increased amounts in the urine of patients
suffering from cancer of the bladder (Boyland and Williams, 1954, 1956). ortho
-Aminophenols are usually excreted as sulphuric esters or as glucuronides in
urine and these compounds would be expected to be inactive as carcinogens
unless hydrolysed by enzymes. The carcinogen concentration would be depen-
dent on the time which the urine remained in the bladder, on the concentration
of ortho-aminophenol conjugates in the urine and on the urinary activity of the
enzymes sulphatase and 8-glucuronidase (Fig. 1). The activity of both sulphatase
and f6-glucuronidase in urine is raised in cancer of the bladder (Boyland, WallaceENZYME ACTIVITY IN RELATION TO CANCER
and Williams, 1955) but urinary sulphatase hydrolyses the sulphuric esters
of some carcinogenic aminophenols only slowly (Boyland, Manson, Sims and
Williams, 1956) and therefore fi-glucuronidase must play a part in the hydrolysis
of such conjugates. If the urinary fi,8-glucuronidase activity in patients, in which
new tumours would be expected to develop, could be inhibited, then these tumours
should be prevented.
The present work deals with the urinary fi-glucuronidase activity of patients
suffering from cancer ofthe bladder and the effect of treatment withfi-glucuroni-
dase inhibitors on the enzyme activity. The inhibitors used are all derived from
glucosaccharic acid, which have been previously shown to inhibit f,-glucuronidase
in vitro (Karunairatnam and Levvy, 1949; Mills and Paul, 1949; and Levvy,
1952). Saccharo-l: 4-lactone (glucosaccharo-l: 4-lactone) is the most effective
inhibitor and the inhibitory action of saccharates used in these investigations is
probably due to the 1: 4-saccharolactone which they contain or is produced
from saccharate in the body. Saccharic acid is readily and reversibly converted
to a mixture of saccharo-1: 4-lactone and saccharo-3: 6-lactone.
Saccharo-l: 4-lactone (II) is formed from saccharic acid (III) by loss of the
elements ofwater. This dehydration reaction which is reversible gives the lactone
(II) which has a structural resemblance to glucosiduronic acids ief. I). Gluco-
saccharo-l: 4-lactone is probably an active inhibitor of fi-glucuronidase because
of this similarity in structure which allows it to occupy the enzyme centre which
is concerned with f,-glucuronidase activity. Glucosaccharo-3: 6-lactone (IV)
which is also formed from saccharic acid and only differs from the 1: 4-lactone,
in the position of hydroxyl groups is a poor inhibitor. (For formulae I to IV
see page 585).
EXPERIMENTAL
The fi-glucuronidase activity is almost always increased in the urine ofpatients
with cancer of the bladder and remains high in most cases even after the tumour
has been removed (Boyland, Wallace and Williams, 1955). The method ofestima-
tion has since been modified (Boyland et al., 1957) in the following ways- (a)
A 20per cent solution of thymol in benzene is used as a preservative as it is more
effective than the benzene used in the original work. (b) The buffer concentration
has been increased so that the activity of alkaline urine specimens (previously
discarded) may also be estimated. The enzyme is unstable in strongly alkaline
solution. The upper limit of the norma] range using this method is 1.2 units/ml.
All f8-glucuronidase values are expressed as units of activity per ml. of urine.
The unit of activity is defined as being that which liberates 1 pg. of phenolph-
thaleinper hour at 37° C. In all cases the total 24 hr. output ofurine was collected
and the test performed on a 1 ml. aliquot of this; the total 24 hr. volume being
also quoted so that the total 24 hr. excretion may be calculated. All patients
included have a history of more than 2 years of cancer.
The treatment ofpatients with enzyme inhibitors
Patients have been treated with a number of inhibitors (supplied by Messrs.
Kemball, Bishop and Co. Ltd., London, E.3) to decrease the /8-glucuronidase
activity in urine. The estimation of urinary f/-glucuronidase involves a 3-fold
dilution so that the apparent inhibition obtained is always less than the actual
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effect in the urine. Patients were treated with solutions ofthe inhibitors flavoured
with "fruit concentrates ".
(a) Calcium gluconate.-The average inhibition of urinary f8-glucuronidase
activity on treatment with 10 g. calcium gluconate is only 15 per cent (Table I).
TABLE I.-Patients Sufferingfrom Cancer of the Bladder Treated with
Calcium Gluconate
Before treatment
Age Vol./24 hr. Units/mi.
59 . 2750 1.8
2750 1.6
. . 63
.... 77
.., . 67
*... . 65
4
5
1400
2350
4000
1800
2000
1950
2750
3500
2750
2900
3100
5.8
5.5
5.8
1.7
1.9
2.0
1.5
1 8
1 2
1.9
2.1
During treatment
Vol./24 hr. Units/mi.
2700 1.2
2500 0 8
2750
2750
2400
2850
2850
3100
2700
3700
3100
2500
3.8 5.8
1.7
1 8
1.6
1-4
1.3
1.4
1.6
1.3
(b) Sodium ammonium saccharate.-A patient with multiple tumours of the
bladder was treated with sodium ammonium saccharate solution (10 g. per day
for 1 week) (Fig. 2). The treatment was then stopped and the /8-glucuronidase
activity rose to the original value within 3 days. The variation in enzyme activity
and the volume ofthe 24 hr. urine specimen is also recorded. The results obtained
from 4 patients treated in a similar manner (Table II) indicate that the treatment
reduced the fl-glucuronidase activity by 31 per cent.
TABLE II.-Patients Sufferingfrom Cancer of the Bladder Treated with
Sodium Ammonium Saccharate
Case No. Sex
1 . M.
2
3
Before treatment
Age Vol./24 hr. Units/mi.
52 . 3700 3-2
4000 2 7
3100 2-6
75
J. . 62
Ps, . 38 4
1700
2000
1800
2500
4300
2700
8000
6700
9250
7300
3'0
2.3
2-3
1.6
1.3
1.7
0.8
1.2
1.2
1.0
During treatment
Vol./24 hr. Units/mi.
3100 1.2
3500 1.7
3900 1.2
3300
2800
1900
2100
3300
3600
3500
4400
2.7
2-0
1.1
1.0
1.1
0 7
0.9
1-9
Case No. Sex
1 . M.
2
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FIoG. 2.-The effect of oral administration of sodium ammonium saccharate on
urinary f-glucuronidase activity in a patient with bladder cancer.
O O f-Glucuronidase activity (units/mi.).
* ......0 Urine volume (litres/24 hr.).
10
Fio. 3.-The effect of oral administration of ammonium hydrogen saccharate on
urinary fl-glucuronidase activity in a patient with bladder cancer.
O O fl-Glucuronidase activity (units/mi.).
* * Urine volume (litres/24 hr.).
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(c) Ammonium hydrogen saccharate.-Treatment of a patient with 10 g. per
day ofammonium hydrogen saccharate (Fig. 3) produced a fall in ,J-glucuronidase
activity of the urine. Treating 6 patients with 3-3 g. of ammonium hydrogen
saccharate 3 times daily produced an average apparent inhibition of the ,-glucu-
ronidase activity of 47 per cent (Table III).
TABLE III.-Patients Sufferingfrom Cancer ofthe Bladder Treated with Ammoniurm
Hydrogen Saccharate
Case No. Sex
1 . F.
Age
51
2 . M. . 54
3
4
5
47
*1 61
56
6 . F. 56
Before treatment
r A - A
Vol./24 hr. Units/ml.
2700 1 4
2850 1-8
2750 1.8
3250 1'6
2520 1- 7
3100 0 50
2850 0-65
3600 1- 8
2500 1-4
1800 1 6
1650 1 7
2750 1- 6
700
700
800
2000
2000
0.55
0 92
2-6
3*6
1 9
During treatment
r
Vol./24 hr. Units/ml.
2750 0 65
2810 0 80
2520 0 70
2750 0 65
2450 0 80
2800 0 30
2700 0-35
2000 1a2
2250 1-0
2100 0 60
2200 0 65
2600 0 80
1600 1-0
2100 1- 25
2600 1.1
(d) Glucosaccharolactone. -(1) A group of patients were treated with a boiled
solution of saccharic acid which contains an equilibrium mixture of saccharic
acid and 3: 6 and 1 : 4 saccharolactones, and received 1-3 g. of saccharo-1 : 4-
lactone 3 times daily. The effect ofthis treatment on the urinary ,6-glucuronidase
activity (Fig. 4 and Table IV) indicates that the mean inhibitionoffl-glucuronidase
activity is 92 per cent.
TABLE IV.-Patients Suffering from Cancer of the Bladder Treated with Boiled
Saccharic Acid Solution
Case No. Sex
1 . M.
2 . F.
3 . ,
Age
54
38
55
4 . M. . 48
5 *13, 34
Before treatment
Vol./24 hr. Units/ml.
2000 0 90
1900 1-3
2600 1*4
1600 1-0
2500 1-4
2650 0 92
2520 1*6
2760 1.0
2550 1- 6
1750 1*0
980 3 6
910 2 7
3060 1- 22
4460 0 96
During treatment
r A- I
Vol./24 hr. Units/ml.
2400 0-01
3100 0 03
3300 0 02
2900 0 00
2500 0 35
2610 0-21
2120 0 14
1800 0 07
1100 0*44
2500 0 06
1010 0O10
1100 0*05
4050 0 08
3700 0 10ENZYME ACTIVITY IN RELATION TO CANCER 583
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Fia. 4.-The effect of oral administration of boiled saccharic acid on urinary
fl-glucuronidase activity in a patient with bladder cancer.
O O fl-Glucuronidase activity (units/ml.).
* ......0 Urine volume (litres/24 hr.).
(2) Treatment of a number of patients with a mixture of glucosaccharo-
1: 4-lactone andglucosaccharo-3: 6-lactone (2.5 g. ofthe mixture conta'mining 1 g.
of the 1: 4-lactone administered 4 times daily) (Table V) caused an average
inhibition of activity of 84 per cent.
TABLE V.-Patients Suffering from Cancer of the Bladder Treated with a Mixture
of Glucosaccharo-1: 4-lactone and Glucosaccharo-3 : 6-lactone
Case No. Sex
1 . F.
Before treatment
I A
I
Age Vol./24 hr. Units/mi.
.- .1825 4 7
1550 10.3
During treatment
Vol./24 hr. Units/ml.
2210 1.6
2140 1.2
2 ,, . 76
3 . M. . 66
4
5
P . 61
,, . 82
1595
1535
1335
2640
2850
2550
2700
2100
1510
1575
7-6
6.1
6.1
6.3 7.3
6*2
2*8 3.1
4.9
3*2
1865
1940
1725
1585
2610
2490
2100
1765
1.3
1'7
0O28
0'56
0 33
0'33
0'71
0'43
(3) The results obtained by treatment of patients with pure saccharo-: 4-
lactone (1 g. 4 times daily) (Table VI) show a mean inhibition of 93 per cent.
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3: 6 mixture on the urinary ,-glucuronidase of patients suffering from cancer of
the bladder is shown in Fig. 5. Specimens of urine were collected from each of 5
patients at approximately 3 hourly intervals and the f-glucuronidase activity of
the individual specimens estimated. In 5 successive periods each of 48 hr. the
Pure Mixed
2None lactone None lactol_e Nonle
'1
2-
?,
U1)
10
2-
I
4
Time(days)
FIG. 5.-The effect of oral administration of glucosaccharo-1 : 4-lactone and mixtures of
1: 4 and 3: 6-lactones on urinary ,-glucuronidase activity in 5 patients with bladder cancer.
O O fl-Glucuronidase activity (units/ml.).
* * P-Glucuronidase activity (units/ml.) in urine containing blood.
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patients were given (1) no treatment, (2) treatment with pure saccharo-l: 4-
lactone (1 g. six hourly), (3) no treatment, (4) treatment with a mixture of
saccharo-l : 4- and 3: 6-lactones/2: 3 (2.5 g. 6 hourly), (5) no treatment. In
Case.4 the urine was contaminated with blood on the seventh day which accounts
for the high result obtained.
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TABLE VI.-Patients Suffering from Cancer of the Bladder Treated with Pure
Glucosaccharo-1 : 4-lactone (1g. 4 times daily)
Case No. Sex
1 . M.
Before treatmnent
Age Vol./24 hr. Units/mi.
53 . 1373 7.4
2013 5.2
1746 7 7
During treatment
Vol./24 hr. Units/ml.
1527 0 84
1855 0-65
2120 0.51
2 ,, . 62
3 . F. . 76
4 . M. . 66
5 . F. . -
6 . M. . 61
7 ..., . 82
2050
1760
2040
1660
2125
2315
2740
1470
1920
1980
2850
1720
1600
7.3
6-3
10.1 7.7 7.1
5.9
6.6
12.6
11-2
3.0
2-8
5.5
4.1
2105
2110
1980
1565
. 2110
2190
1695
2120
1870
1560
1590
0-88
0-22
0-60
0'90
0- 88
0-64
0-44
0-48
0-32
0-22
0-37
(4) The results obtained by treating patients with pure saccharo-l : 4-lactone
(0.5 g. 3 or 4 times daily) (Table VII) show a mean inhibition of 73 per cent and
the effect on individual urine specimens of treating patients with 0-5 and 1 g. of
saccharo-l : 4-lactone 8 hourly is shown in Fig. 6.
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FIG. 6.-The effect of oral administration of pure glucosa¢charo-1: 4-lactone on
urinary ,-glucuronidase activity in 3 patients with bladder cancer.
O O f-Glucuronidaae activity (units/mi.).
None
^ b z - b <
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TABLE VII.-Patients Suffering from Cancer of the Bladder Treated with Pure
Glucosaccharo-l: 4-lactone
Before treatment During treatment
A
Case No. Sex Age Vol./24 hr. Units/mi. Vol./24 hr. Units/mi.
(a) Dose 4 x 0.5 g./day)-
1 . M. . 52 . 2720 1.1 . 2780 0*12
2585 0.83 . 2740 0-12
2 . ,, . 63 . 1415 1.5 . 1205 0.16
1600 4.4 · - -
3 . F. . 43 . 1100 0.53 . 1550 0.06
1700 0.38 . 1835 0.13
(b) (Dose 3 X 0O5 g./day)-
1 . M. . 43 . 1330 6.5 . 1515 3.8
1205 6.9 . 1405 3'1
2 . ,, . 55 . 2350 1.4 . 2140 0 17
1560 1.5 . 2310 0O25
3 . 68 . 2800 0 93 . 1830 0.10
1590 1.0 . 2060 0 22
4 . ,, . 71 . 2360 1.7 . 2290 0 37
1519 1.9 . 2750 0.47
Theresultsindicate thattheurinaryfl-glucuronidaseactivity canbemaintained
at a low level by the administration ofeither the pure 1: 4-lactone or the mixture
of lactones. Patients are being treated with 1 g. saccharo-l: 4-lactone t.d.s.
for clinical trials.
DISCUSSION
The urinary /?-glucuronidase activities of patients who have been suffering
from cancer of the bladder for some years are almost all raised above the corre-
sponding value for normal subjects. The increased activity does not depend upon
infection although, in a few cases infected by B. coli, this may play some part.
The enzyme is stable up to pH 9.0 and the method of estimation allows urine of
pHlessthanthisvaluetobeused. Theresults areinagreementwiththoseobtained
previously (Boyland et al., 1955) using an earlier technique.
The urinary /6-glucuronidase activity of patients with cancer of the kidney
(hypernephroma) islowcomparedwiththat ofbladder cancerpatients, the average
value being within the normal range. Fishman and his co-workers have shown
that cancer cells have ahigh,-glucuronidase activity but the high urinary activity
in cancer ofthe bladder cannot bedue to the urine being in contact with malignant
tissue as urine from patients with cancer of the kidney should also be rich in
fl-glucuronidase. This evidence further supports the suggestion (Boyland et al.,
1955) that the increased urinary enzyme concentration is probably derived from
the blood, the amount of the enzyme depending both on the blood concentration
and the degree to which the enzyme passes through the kidney. The relationship
between the 8-glucuronidase activities of serum and urine ofpatients with cancer
ofvarying sites is being investigated further.
Patients suffering from cancer of the bladder have been treated with gluco-
saccharo-1: 4-lactone (4 g. per day) which reduces the activity by 90 per cent.
This inhibition of/-glucuronidase would be produced with a 5 x 10-5 M saccharo-
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1: 4-lactone solution (Levvy, 1952) which is equivalent to about 10 mg. per litre.
This indicates that only 0.5 per cent of the dose administered is excreted in the
urine. The greater part (99.5 per cent) of the lactone is inactivated either by
metabolic processes or reaction with water or other body constituents. This
treatment reduced the urinary ,-glucuronidase level to values below the average
normal level and by this means it is hoped to decrease the amount offree carcino-
gensintheurine andthusreducetheincidence ofnewtumours inpatients,whohave
had tumours removed. Twenty bladder cancer patients are at present under
treatment with glucosaccharo-l: 4-lactone, but this treatment has not been
used long enough to allow any conclusions to be drawn as to the clinical benefit.
The authors realise that to treat patients who have had cancer of the bladder
with compounds which will reduce the concentration of carcinogenic agents in
the urine, is probably to act too late. Because ofthe long lag between the applica-
tion ofthe carcinogenic stimulus andthe occurrence ofthe cancer, the first stimulus
had probably taken effect before treatment began. This is, however, not certain
and the reduction of carcinogens in the urine may reduce the chance of tumours
developing. The tumours may, however, be dependent on the continued presence
ofthe carcinogen in the way that the growth ofkidney tumours, induced in ham-
sters with stilboestrol is dependent on the continued presence of stilboestrol
(Horning, 1956). If the tumours of the bladder were dependent on the urinary
carcinogen then treatment with saccharo-l: 4-lactone could prevent growth of
established tumours.
Bladder cancer caused by aromatic amines among men in the chemical industry
is probably due to metabolites of the aromatic amines being hydrolysed by
f/-glucuronidase in the urine to give aminophenols. Stringent precautions are now
taken in the chemical industry to prevent exposure to the carcinogenic amines.
Insuchfactories, however, ifaccidentshappen the carcinogenic effectofexposure of
personnel should be reduced by administration of saccharo-l: 4-lactone immedi-
ately following the exposure and for four or five days. In such cases the treatment
should prevent the liberation ofthe carcinogen in the urine.
SUMMARY
The in vivo effect of various derivatives of saccharic acid which arefl-glucuro-
nidase inhibitors has been investigated; oral administration of 1 g. saccharo-1: 4-
lactone every 6 hours decreases the enzyme activity in the urine by 90 per cent.
Treatment with saccharolactone should therefore reduce the liberation of free
carcinogenic aminophenols in urine. Such treatment is recommended for men
accidentally exposed to carcinogenic aromatic amines and is being tried in
prophylactic treatment of patients who have had bladder cancers removed or
destroyed.
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